Metraipolis › archive › dc_832cd3ec1da5

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model — Europe PMC PMID:42306793

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42306793
DOI
10.3389/fonc.2026.1820206
License (as archived)
solo-consultazione
Archived
2026-10-31T21:13:38.459Z
SHA-256 of the archived text
dba63b8156282d45f3b1d1392fb79d81b87db5ff1b72cddc592b10c468bd2fe9
Stable URL of this page
https://metraipolis.com/documento/dc_832cd3ec1da5

How to cite

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model — Europe PMC PMID:42306793 — Europe PMC (en), https://europepmc.org/article/MED/42306793 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_832cd3ec1da5 (Metraipolis archive dc_832cd3ec1da5, sha256 dba63b8156282d45f3b1d1392fb79d81b87db5ff1b72cddc592b10c468bd2fe9)
BibTeX
@misc{dc832cd3ec1da5,
  title = {Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model — Europe PMC PMID:42306793},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42306793},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_832cd3ec1da5; sha256 dba63b8156282d45f3b1d1392fb79d81b87db5ff1b72cddc592b10c468bd2fe9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42306793. Agents can read the archived copy with the MCP tool read_document.